Company / Cash & Equivalents
Mereo BioPharma Group plc Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$41.0M
FY2025
5-year range
$41.0M / $69.8M
FY2023-FY2025
Trend
-41.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $57M to $41M over the past 2 years.
Based on SEC 10-K filings.
$41M in FY2025.
Declined from $57M to $41M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 41.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.0M | -41.3% |
| FY2024 | $69.8M | +21.6% |
| FY2023 | $57.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 27, 2026